Roche : new up leg in sight ?
Nicolas Suiffet June 19, 2020 8:33 AM
Roche, the pharmaceutical giant, said a phase 3 study, evaluating its ipatasertib in combination with abiraterone and prednisone/prednisolone, met the co-primary endpoint of radiographic progression-free survival (rPFS).
Roche, the pharmaceutical giant, said a phase 3 study, evaluating its ipatasertib in combination with abiraterone and prednisone/prednisolone, met the co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer, but the other co-primary endpoint of rPFS in the overall study population was not met.
From a chartist's point of view, the short term consolidation started in May could be over as prices have landed on a key support at 320CHF and are posting a rebound. The breakout confirmation of the 20DMA is a bullish event. The daily Relative Strength Index (RSI, 14) is pushing above its declining trend line. The general up trend remains in place.
Readers may want to consider the potential for long positions above the horizontal support at 320CHF with 351CHF and 358CHF as targets. Alternatively, a break below 320CHF would invalidate the bullish trend and would call for a down move towards 298CHF.
Source: GAIN Capital, TradingView
Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.
Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to Forex.com or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.